


Contact us at sales@chicagodiscoverysolutions.com/ 1-815-609-2071

Recommended Reading- Privileged scaffolds for library design and drug discovery
Current Opinion in Chemical Biology 2010, 14:1–15, Matthew et al.

For specific examples of privileged structures see references below:

- [7,592,359](#)  [Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists](#)
- [7,560,479](#)  [3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists](#)
- [7,544,708](#)  [Azabicyclo derivatives as muscarinic receptor antagonists](#)
- [7,531,545](#)  [2-amino-3,4-dihydro-pyrido\[3,4-d\]pyrimidine derivatives useful as inhibitors of .beta.-secretase \(BACE\)](#)

- [7,517,905](#)  [Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists](#)
- [7,501,443](#)  [Flavaxate derivatives as muscarinic receptor antagonists](#)
- [7,488,748](#)  [3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists](#)
- [7,465,751](#)  [1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists](#)
- [7,446,123](#)  [Azabicyclo derivatives as muscarinic receptor antagonists](#)
- [7,410,993](#)  [3,6-disubstituted azabicyclo \[3.1.0\] hexane derivatives useful as muscarinic receptor antagonists](#)
- [7,399,779](#)  [3,6-disubstituted azabicyclo \[3.1.0\] hexane derivatives useful as muscarinic receptor antagonists](#)
- [7,288,562](#)  [Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo \(3.1.0\) hexane derivatives as muscarinic receptor antagonists](#)
- [7,265,147](#)  [3,6-disubstituted azabicyclo \[3.1.0\]hexane derivatives useful as muscarinic receptor antagonists](#)
- [7,232,835](#)  [3,6-Disubstituted azabicyclo derivatives as muscarinic receptor antagonists](#)
- [6,812,344](#)  [1-\(4-Arylpiperazin-1-yl\)-.omega.-\[N-\(.alpha.,.omega.-dicarboximidoL\)\]-alkanes useful as uro-selective .alpha.1-adrenoceptor blockers](#)
- [6,734,307](#)  [Oxazolidinone derivatives as antimicrobials](#)

- [6,420,559](#)  [1-\(4-arylpiperazin-1-yl\)-.omega.-\[N-\(.alpha.,.omega.-dicarboximido\)\]-alkanes useful as uro-selective .alpha.1-adrenoceptor blockers](#)
- [6,420,366](#)  [1-\(4-arylpiperazin-1-yl\)-.omega.-\[N-\(.alpha.,.omega.-dicarboximido\)\]-alkanes useful as uro-selective .alpha.1-adrenoceptor blockers](#)
- [6,410,735](#)  [1-\(4-arylpiperazin-1-yl\)-.omega.-\[N-\(.alpha.,.omega.-dicarboximido\)\]-alkanes useful as uro-selective .alpha.1-adrenoceptor blockers](#)

- [6,090,809](#)  [1-\(4-arylpiperazin-1-yl\)-.omega.-\[n-\(.alpha.,.omega.-dicarboximido\)\]-alkanes useful as uro-selective .alpha..sub.1 -adrenoceptor blockers](#)
- [6,083,950](#)  [1-\(4-arylpiperazin-1-yl\)-.omega.-\[n-\(.alpha.,.omega.-dicarboximido\)\]-alkanes useful as uro-selective .alpha.1-adrenoceptor blockers](#)

For Specific Use of some privileged structures see references below: